Linked Life Data

21354972

Source:http://linkedlifedata.com/resource/pubmed/id/21354972

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21354972rdf:typepubmed:Citationlld:pubmed
pubmed-article:21354972lifeskim:mentionsumls-concept:C0026769lld:lifeskim
pubmed-article:21354972lifeskim:mentionsumls-concept:C0012655lld:lifeskim
pubmed-article:21354972lifeskim:mentionsumls-concept:C1706299lld:lifeskim
pubmed-article:21354972lifeskim:mentionsumls-concept:C0205419lld:lifeskim
pubmed-article:21354972lifeskim:mentionsumls-concept:C1421249lld:lifeskim
pubmed-article:21354972lifeskim:mentionsumls-concept:C1326152lld:lifeskim
pubmed-article:21354972pubmed:issuePt 3lld:pubmed
pubmed-article:21354972pubmed:dateCreated2011-2-28lld:pubmed
pubmed-article:21354972pubmed:abstractTextThe tyrosine kinase 2 variant rs34536443 has been established as a genetic risk factor for multiple sclerosis in a variety of populations. However, the functional effect of this variant on disease pathogenesis remains unclear. This study replicated the genetic association of tyrosine kinase 2 with multiple sclerosis in a cohort of 1366 French patients and 1802 controls. Furthermore, we assessed the functional consequences of this polymorphism on human T lymphocytes by comparing the reactivity and cytokine profile of T lymphocytes isolated from individuals expressing the protective TYK2(GC) genotype with the disease-associated TYK2(GG) genotype. Our results demonstrate that the protective C allele infers decreased tyrosine kinase 2 activity, and this reduction of activity is associated with a shift in the cytokine profile favouring the secretion of Th2 cytokines. These findings suggest that the rs34536443 variant effect on multiple sclerosis susceptibility might be mediated by deviating T lymphocyte differentiation toward a Th2 phenotype. This impact of tyrosine kinase 2 on effector differentiation is likely to be of wider importance because other autoimmune diseases also have been associated with polymorphisms within tyrosine kinase 2. The modulation of tyrosine kinase 2 activity might therefore represent a new therapeutic approach for the treatment of autoimmune diseases.lld:pubmed
pubmed-article:21354972pubmed:languageenglld:pubmed
pubmed-article:21354972pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21354972pubmed:citationSubsetAIMlld:pubmed
pubmed-article:21354972pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21354972pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21354972pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21354972pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21354972pubmed:statusMEDLINElld:pubmed
pubmed-article:21354972pubmed:monthMarlld:pubmed
pubmed-article:21354972pubmed:issn1460-2156lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:WeberFrankFlld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:SaoudiAbdelha...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:FontaineBertr...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:OksenbergJorg...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:RieckmannPete...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:Cournu-Rebeix...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:MontalbanXavi...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:ConfavreuxChr...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:Müller-Myhsok...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:ComabellaManu...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:VukusicSandra...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:MarsLennart...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:LiblauRoland...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:EdanGillesGlld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:MoreauThibaul...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:NurtdinovRami...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:ClanetMichelMlld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:DeferGillesGlld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:ZettlUwe KUKlld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:BrassatDavidDlld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:DebouverieMar...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:CouturierNico...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:BucciarelliFl...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:Lebrun-Frenay...lld:pubmed
pubmed-article:21354972pubmed:authorpubmed-author:GoertschesRob...lld:pubmed
pubmed-article:21354972pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21354972pubmed:volume134lld:pubmed
pubmed-article:21354972pubmed:ownerNLMlld:pubmed
pubmed-article:21354972pubmed:authorsCompleteYlld:pubmed
pubmed-article:21354972pubmed:pagination693-703lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:meshHeadingpubmed-meshheading:21354972...lld:pubmed
pubmed-article:21354972pubmed:year2011lld:pubmed
pubmed-article:21354972pubmed:articleTitleTyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility.lld:pubmed
pubmed-article:21354972pubmed:affiliationINSERM U563 and Pôle des neurosciences, University of Toulouse 3, 31000 Toulouse, France.lld:pubmed
pubmed-article:21354972pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21354972pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:7297entrezgene:pubmedpubmed-article:21354972lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21354972lld:entrezgene